Introduction
In the past decade the possibility of modulating the intestinal microflora through the use of probiotics, such as bacilli, Escherichia coli spp., enterococci, bifidobacteria, lactic acid bacteria species, and yeasts to improve health has attracted much interest. They have been demonstrated to be effective in preventing and reducing the severity of infectious acute diarrhoea, antibiotics-associated diarrhoea, in relieving symptoms of lactose maldigestion, in an improvement of food allergies and atopy, in the treatment of infections of the urogenital tract, in the maintenance of remission and cure of pouchitis in inflammatory bowel disease (IBD) and in colon cancer prevention. However, potential clinical applications are currently both at the gastrointestinal and extraintestinal stage on the basis of clinical observations [1] [2] [3] . Nevertheless, the presence of bacteria in the intestinal lumen has been demonstrated to create an epithelium-bacteria interaction that induces unique host responses [4, 5] .
Among the different microorganisms, Bacillus species (Bacillus cereus, Bacillus clausii, Bacillus pumilus) were characterized for their potential attributes (colonization, immunostimulation, and antimicrobial activity), which could account for their claimed probiotic properties. In particular, B. clausii presents several unique properties and a long history of safe use. This probiotic is resistent to commonly used antibiotics, and has been administered to humans for the prevention of gastrointestinal side-effects caused by oral antibiotic chemotherapy [6] [7] [8] . B. clausii is carried in a commercial probiotic product consisting of bacterial spores, although they are generally absent from the normal microflora of humans. Experimental data also suggest that B. clausii spores can adhere to the bowel wall, allowing mucosal colonization [9, 10] . Moreover, B. clausii strains release antimicrobial substances, active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile [11] . Besides, in a study conducted to investigate the modulation of the cytokine pattern after B. clausii administration in allergic children with recurrent respiratory infections [12] , this probiotic was demonstrated to exert immunomodulatory activities.
Therefore, studies aimed at characterizing the mechanisms responsible for the probiotic beneficial effects of B. clausii are rare.
To date, recent advances in complementary DNA microarray technology allow the comparative messenger RNA analysis of thousands of genes in multiple samples simultaneously, enabling the evaluation of a wide pattern of gene expression [13] .
In the present study, we investigated the effect of B. clausii on the gene expression profile in the small bowel mucosa of healthy individuals using the U133A microarray set by Affymetrix Inc. (Santa Clara, CA, USA).
Materials and methods
Six male patients (mean age 38 ± 5 years) affected by mild oesophagitis (Savary-Miller grade I) and no gastric or duodenal alterations at endoscopy were included in the study. Signed informed consent was obtained from each individual before entering the study.
The patients were then divided into two groups to receive: group I (three patients), B. clausii, three vials/day each containing 2 Â 10 9 spores (5 ml) (Sanopy Synthelabo OTC SpA, Sanopy-aventis Group, Milan, Italy) and proton-pump inhibitor (PPI) (esomeprazole 40 mg twice a day) for 30 days; group II (three patients), PPI for 30 days. Two additional patients were enrolled and treated as group I, in order to confirm the microarray data by realtime reverse transcriptase-polymerase chain reaction (RT-PCR) on five patients' samples (before and after treatment). Biopsies from each patient were collected from distal duodenal mucosa pre and post-treatment to assess the modification induced by B. clausii on the gene expression pattern.
DNA microarray analysis
Each biopsy has been measured separately. Total RNA was extracted from each sample using Trizol lysis buffer (Invitrogen, Carlsbad, CA, USA). Doublestranded cDNA was synthesized from 5 mg of total RNA, using the Superscript Choice system (Invitrogen). After cDNA purification, labelling of complementary RNA was achieved using the ENZO Bioarray High Yield RNA Transcript Labeling kit (ENZO Biochem, New York, NY, USA). In vitro transcription (IVT) reactions were carried out at 371C for 4.5 h. The purified (RNeasy Mini Kit) cRNA was fragmented (buffer: 200 mmol/l Trisacetate pH 8.1; 500 mmol/l potassium acetate; 150 mmol/l magnesium acetate) at 951C for 35 min. The biotinylate targets (11 mg/probe array) were hybridized to the Human Genome U133A array set (Affymetrix), which contains 22 215 human gene cDNA probes, in a hybridization mixture containing probe array controls, bovine serum albumin and herring sperm DNA. Hybridization was allowed to continue for 16 h at 451C. After washing and staining, the arrays were scanned twice using an HP GeneArray Scanner (Hewlett-Packard, Palo Alto, CA, USA), and the average of the intensities was used to evaluate the signal value. GeneChip expression software (Affymetrix) was used to determine the absolute analysis metrics. A set of 'housekeeping genes', such as GAPDH and beta-Actin, was used for normalization.
The gene expression profiles were tested in all biopsies collected for each patient before and after B. clausii administration. For statistical analysis, we first evaluated the differences in gene expression comparing the pre and post-treatment data of the patients treated with B. clausii and PPI (group I). Then, to differentiate the genes modified by the probiotic from those modified by PPI, group I and group II were compared. To be considered a 'significantly changed gene', a gene had to satisfy the following criteria: absolute expression level (to eliminate background); difference in the expression level of each gene across samples (before versus after treatment for each patient; at least 200); fold change for each gene in each patient (before versus after treatment), or whether gene expression has been up or downregulated (at least twofold change); reproducibility of the measurements, or whether samples with similar characteristics had similar amounts of gene transcript [14] .
Significant differentially expressed genes were also grouped on the basis of molecular function (tasks performed by the individual gene product) and biological processes (broad biological goals accomplished by ordered assemblies of molecular functions) using the DAVID database [15] .
Real-time SYBR-green dye I real-time polymerase chain reaction analysis
Five target genes were subjected to confirmation by SYBR-green dye I real-time RT-PCR. For polymerase chain reaction (PCR) analysis we enrolled two additional patients following the inclusion criteria and the treatment protocol of group I. The selected genes plus GAPDH and the primers designed on the basis of the GeneBank sequences using Primers3 software are reported in Table 1 .
The total RNA (200 ng) retrieved from each biopsy of group I and the total RNA extracted from the two additional patients enrolled was used. The cDNA (for each sample) was synthesized using a Superscript First Strand cDNA synthesis kit (Invitrogen). Each PCR system (25 ml) contained 2 ml diluted cDNA, 12.5 ml 2 Â SYBR-green PCR Master Mix, 0.5 mmol/l of each specific gene primer and water and 1.25 U AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems, Norwalk, CT, USA). Real-time PCR was performed and analysed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). All the samples were run in triplicate in the amplification programme, and the average amount was used as the final expression value. A negative control without the cDNA template was run to assess the overall specificity. Melting curves for each PCR were generated to ensure the purity of the amplification product ( Fig. 1 ). Products were double-checked by run on an ethidium bromide staining in agarose gel. A standard curve method (generated preparing serial dilutions of total cDNA) was used to calculate the relative amounts of target gene expression. All the samples were run in triplicate, and the average was considered to be the final value. Quantities of each target gene were normalized to the corresponding GAPDH.
Results

DNA microarray analysis
After B. clausii administration, 92 and 265 genes showed greater than twofold up and down changes, respectively. B. clausii mainly affected genes involved in immune response and inflammation, apoptosis and cell growth, Table 1 Gene-specific primers for the real-time SYBR-green analysis selected according to the manufacturer's recommendations (Applied Biosystems)
Gene
Forward primer Reverse primer cell adhesion, transcription, cell communication, defence response and cell cycle, as shown in Table 2 .
Those genes were grouped, on the basis of the molecular and biological functions exerted, as genes working in a similar context (Table 3) . The differentially expressed genes were thus categorized on the basis of their known function. As an example, a group of 31 modified genes are related to transcription. Some of them are also involved in cell proliferation, cell growth and cell adhesion, such as cadherin 6, MAX dimerization protein 1 and v-jun.
Another category with a large number of changed genes included those involved in immune regulation and inflammatory response, such as IL-1b, Hsp40, proteoglycan 2, sialophorin, cathepsin S, defensin 126, cysteinerich protein 1, MPA4K4, H factor 1, TNF receptor superfamily, member 17, IL-1 and IL-1 receptor, IL-6 receptor, IL-15 receptor a, IL-13, somatomedin C, and plasminogen activator. Moreover, several altered genes play a role in cell growth, apoptosis, and cell cycle, such as growth differentiation factor 3, RAS oncogene family member RAB6A, jagged 2, hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF)-1, cyclin E1 and D1, somatostatin, HUS1 checkpoint homolog, NIMA (never in mitosis gene a)-related kinase 9, MAX dimerization protein 1, myeloperoxidase, BCL2-antagonist of cell death, caspase 5 and 6, and programmed cell death 6 interacting protein.
Fifteen and 12 genes followed the same pattern of up and downregulation, respectively, in both group I and group II. However, as those genes are involved in multiple cellular functions and do not appear to affect the unique cellular pathways preferentially, they were excluded from the analysis.
Real-time SYBR-green analysis
Quantitative real-time RT-PCR confirmed the reliability of the microarray analysis. As shown in Figure 2 , there was a very high level of agreement between the two methodologies used, and the expression changes were qualitatively similar, supporting the validity of our results. However, the magnitude of the gene expression alterations differed between the two analytical methods.
Discussion
Intestinal mucosa homeostasis mainly depends on the interaction among the resident flora, the epithelium and the immune system. Interest in nutritional supplements and functional foods has increased significantly in recent years, based on the hypothesis that probiotic bacteria in particular may modulate the intestinal flora and the mucosal immune response. Probiotics are defined as live microorganisms that confer a health benefit to the host [16] . The beneficial effects attributed to probiotics undoubtedly require a biochemical communication between the microorganisms and the enterocytes [17, 18] . Therefore, a basic understanding of the consequences of probiotic-epithelial cross-talk is necessary to delineate the role of probiotic agents in health as well as in disease to support clinical decisions scientifically.
Among the most common probiotics used, B. clausii has a long history of use, with over 40 years of clinical application and excellent tolerability. However, the mechanisms of action of B. clausii and how it affects the intestinal mucosa need to be clarified.
The present study shows for the first time the distinctive pattern of gene expression that characterizes the intestinal mucosa after B. clausii administration. The clinical benefits observed with probiotic use are mainly attributed to the antimicrobial substances produced by probiotic strains and to their immunomodulatory effect. The last is based on a bacterial-mucosal interaction. The GeneChip Human U133A microarray set from Affymetrix, which represents approximately 22 000 transcribed genes, was used to identify target genes of B. clausii activity, comparing the gene expression profiles in the small bowel mucosa of three healthy individuals before and after probiotic treatment. Real-time PCR was performed for five target genes and confirmed the reliability of microarray data.
The expression of genes involved in widely diverse functions was modified by B. clausii treatment. Interestingly, genes involved in inflammation, immune response, defence response, intestinal permeability, cell adhesion, cell growth, cell differentiation, cell-cell signalling, apoptosis, signal transcription and transduction, were affected by probiotics.
For example, among genes implicated in the defence response, defensin 126 beta expression was induced after treatment. Defensins are thought to play a major role in the defence of small intestinal crypts against colonization by potential pathogens [19] . Moreover, a lack of the induction of inducible beta-defensins has been indicated in Crohn's disease [20] . Another upregulated gene was leukosialin, a sialoglycoprotein on the surface of human T lymphocytes, monocytes, granulocytes, and some B lymphocytes, which appears to be important for immune function and may be part of a physiological ligandreceptor complex involved in T-cell activation [21] .
Several studies have reported that probiotics are able to regulate anti and pro-inflammatory cytokine production. Moreover, data in the literature report that some strains of probiotic may act differently as immunomodulatory agents pro-T helper type 2 or pro-T helper type 1 type immune response [22] . The importance of this modulation is suggested by the fact that, for example, Crohn's disease is associated with T helper type 1 cytokine production, such as IFN-g, TNF-a and IL-12, whereas ulcerative colitis is linked to a cytokine pattern that is less clear but seems to be a modified T helper type 2 response, with the production of IL-5, IL-10 and IL-13 [18] . Moreover, atopic diseases such as asthma are characterized by a T helper type 2 response [23] . Our results suggest that unique immunomodulatory properties of each probiotic strain should be characterized when developing clinical applications for extended target populations. In particular, B. clausii appears to have a trend for the stimulation of a pro-T helper type 2 pattern of genes. This result seems in contrast with a previous study present in literature, in which the immunomodulatory effects of B. clausii were tested in the nasal mucosa of allergic children [12] . Within the cytokine pattern, IL-6 and IL-15 receptors (downregulated) and IL-13, IL-1b and its receptor (upregulated) were affected by B. clausii. IL-6 is a potent pro-inflammatory cytokine that regulates cell growth and differentiation and plays an important role in the immune response [24] . IL-15 receptor alpha is reported to enhance cell proliferation and the expression of apoptosis inhibitors BCL2L1/BCL2-XL and BCL2 [25] . Abnormalities of IL-15 expression have been described in patients with rheumatoid arthritis or IBD [26] . IL-13, instead, is involved in several stages of B-cell maturation and differentiation and downregulates macrophage activity, thereby inhibiting the production of proinflammatory cytokines and chemokines [27] . The last cytokine affected, IL-1, is produced by activated macrophages and is an important mediator of the inflammatory response, involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis [28] . Most of the previously described genes play a crucial role in inflammatory pathways. Inflammation is a key process involved in the response to pathogens in the bowel. However, it has been demonstrated that chronic or recurrent mucosal inflammation may initiate and promote the development of colon cancer, such as in IBD. Homeostasis in the immune system depends on a balance between the responses that control infection and tumour growth and the reciprocal responses that prevent inflammation and autoimmune diseases.
Other genes affected by B. clausii, involved in the inflammatory cascade, are family members of nuclear factor kappa B (NF-kB), mitogen-activated protein kinases (MAPK), nitric oxide synthase (NOS) and TNF. The NF-kB transcription factor is crucial in the induction of pro-inflammatory gene expression, leading to the synthesis of cytokines, adhesion molecules, chemokines, growth factors and enzymes [29, 30] . This factor has been recognized to be an important regulator in IBD [31] . The overall role that nitric oxide plays in intestinal inflammation, instead, is still unclear [32] . However, recent data demonstrated that NOS plays an important role in limiting injury to the intestine during experimental colitis [33] . The MAPK family of signal transduction proteins is an important intracellular mediator of inflammation, and recently a MAPK inhibitor was successfully used for the treatment of patients with Crohn's disease [34] .
Another gene enhanced by B. clausii administration is JUN, which interacts directly with specific target DNA sequences to regulate gene expression [35] .
Furthermore, in post-treatment specimens we found a remarkable variation in the expression of a group of genes regulating cell fate. Interestingly, the dysregulation of cell cycle progression, angiogenesis and apoptosis (programmed cell-death) processes are involved in tumorigenesis. B. clausii seems to favour cell proliferation and has an anti-apoptotic trend. Among the upregulated genes, MAD competes with MYC for binding to MAX to form a sequence-specific DNA-binding complex, and is a candidate tumour suppressor gene [36] . Also the HUS1 gene was upregulated and is involved in cell cycle arrest in response to DNA damage [37] .
Several growth factors were enhanced by B. clausii, such as growth differentiation factor 3, a member of the transforming growth factor (TGF)-b superfamily, IGF-I, FGF, and HGF. All of them are potent mitogens that have been demonstrated to stimulate the proliferation of epithelial and non-epithelial cells, to promote intestinal wound healing and to exert trophic effects within the intestine [38] [39] [40] . Interestingly, the administration of HGF ameliorated many of the features of bowel disease in a rat model [41] . Moreover, the interplay between serum IGF-1 and IL-1b and IL-6 in IBD, all genes affected by B. clausii, has been studied by Street et al. [42] , who demonstrated a relationship between IGF-1 levels and interleukin levels, disease activity and anatomical distribution, consistent with active inflammation. Conversely, the expression of somatostatin, a negative regulator of cell proliferation, was decreased by B. clausii.
Other genes involved in the regulation of the cell cycle, but downregulated after treatment, are Jagged 2, cyclin D1 and E1, caspase 6 and BAD. Jagged 2 is a member of the Notch gene family that are critical for various cell fate decisions, including cell growth, cell differentiation, cellcell signalling, cell proliferation and migration [43] . The BAD gene, instead, which is a member of the BCL-2 family, positively regulates cell apoptosis by forming heterodimers with BCL-XL and BCL-2, and reversing their death repressor activity [44] . Moreover, the caspase 6 gene, a member of the caspase family that plays a central role in initiating, amplifying, executing apoptosis and in the immunological response was repressed by the probiotics, whereas caspase 5 expression was enhanced [45] . The other downregulated genes belong to the highly conserved cyclin family, such as cyclin D1 and E1. Both of them are required for cell cycle G1/S transition. Mutations, amplification and overexpression of these cyclins, which alter cell cycle progression, are observed frequently in a variety of tumours and may contribute to tumorigenesis, including the multistep process of gastrointestinal carcinogenesis [46] .
Nevertheless, B. clausii also affected genes involved in signal transduction, such as calcium/calmodulin family members CAMK2B and CAMKK2, which are serine/ threonine protein kinases, and regulators of cell adhesion and migration, such as cadherin 6, fibronectin and villin 2, which play a key role in cell surface structure adhesion, migration, and organization. The cell-cell signalling pathway, which includes a series of surface events, and the activation of distinct signal transduction pathways, is crucial for regulating intestinal homeostasis. In the human small intestine, the proliferation, migration, differentiation and death of epithelial cells are influenced by extracellular matrix proteins [47] . Interestingly, microtubule-associated protein, first identified by its binding to the APC protein that is often mutated in colorectal cancer, has been found to respond to treatment [48] .
The purpose of this study was to generate a highly reliable pool of genes whose expression is closely associated with B. clausii administration, and consequently, with B. clausii effects on the host. Therefore, we are now faced with the challenge of understanding how variations in gene expression after probiotic administration contribute to clinical effects and the mechanisms by which the probiotics affect the genes involved in various biological functions.
Furthermore, we evaluated the effects of a specific probiotic strain in healthy subjects, and it is reasonable to suppose that different probiotic preparations, different tracts of intestine, different conditions, i.e. inflammation or atopy, and other factors may contribute to the gene expression profile, with the subsequent activation of specific cellular pathways and unique clinical consequences.
However, the small number of samples analysed represents the major limitation of the study. For this reason a gene has to satisfy four selection criteria (not only the fold change value) to be considered as 'significantly changed' after treatment.
Our data provide for the first time the panel of genes modified in the intestinal mucosa after B. clausii exposure, and represent the first methodological approach to basic research on the consequences of probiotics addressing various biological functions, in order to lay the basis for the future comprehension of mechanisms of action and to support clinical decisions.
